Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2001 and is headquartered in New York, New York.

Period	PE Ratio
2016-09-30	-6.50
2017-09-30	N/A
2018-09-30	N/A
2019-09-30	N/A
2020-09-30	-6.07
2021-09-30	-5.06
2022-09-30	N/A
2023-09-30	-4.55
2024-09-30	-5.25
2025-09-30	-5.06

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVXL	$2.73	+2.25%	8.91M
3
4
5

Anavex Life Sciences Corp. (AVXL) PE Ratio

PE Ratio Data

Get Anavex Life Sciences Corp. Data in Excel

More AVXL Financial Data